Publication Listing for the MeSH term cancer therapy. Found 7 abstracts
Wang J, Lai B, Nanayakkara G, Yang Q, Sun Y, Lu Y, Shao Y, Yu D, Yang WY, Cueto R, Fu H, Zeng H, Shen W, Wu S, Zhang C, Liu Y, Choi ET, Wang H, Yang X. Experimental Data-Mining Analyses Reveal New Roles of Low-Intensity Ultrasound in Differentiating Cell Death Regulatome in Cancer and Non-cancer Cells via Potential Modulation of Chromatin Long-Range Interactions. Frontiers in oncology. 2019 Jan;9:600. PMCID: PMC6640725 |
Caruso LB, Martin KA, Lauretti E, Hulse M, Siciliano M, Lupey-Green LN, Abraham A, Skorski T, Tempera I. Poly(ADP-ribose) Polymerase 1, PARP1, modifies EZH2 and inhibits EZH2 histone methyltransferase activity after DNA damage. Oncotarget. 2018 Feb 13;9(12):10585-605. PMCID: PMC5828221 |
Lu W, Liu Y, Ma H, Zheng J, Tian S, Sun Z, Luo L, Li J, Zhang H, Yang ZJ, Zhang X. Design, Synthesis, and Structure-Activity Relationship of Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Potent Smoothened Antagonists with in Vivo Activity. ACS chemical neuroscience. 2017 Sep 20;8(9):1980-94. |
Wagner J, Kline CL, Ralff MD, Lev A, Lulla A, Zhou L, Olson GL, Nallaganchu BR, Benes CH, Allen JE, Prabhu VV, Stogniew M, Oster W, El-Deiry WS. Preclinical evaluation of the imipridone family, analogues of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212. Cell cycle (Georgetown, Tex). 2017 Oct 02;16(19):1790-9. PMCID: PMC5628644 |
Meng MB, Wang HH, Cui YL, Wu ZQ, Shi YY, Zaorsky NG, Deng L, Yuan ZY, Lu Y, Wang P. Necroptosis in tumorigenesis, activation of anti-tumor immunity, and cancer therapy. Oncotarget. 2016 Aug 30;7(35):57391-413. PMCID: PMC5302997 |
Chen ML, Xu PZ, Peng XD, Chen WS, Guzman G, Yang XM, Di Cristofano A, Pandolfi PP, Hay N. The deficiency of Akt1 is sufficient to suppress tumor development in Pten(+/-) mice. Genes & development. 2006 Jun;20(12):1569-74. |
Brando C, Mukhopadhyay S, Kovacs E, Medina R, Patel P, Catina TL, Campbell KS, Santoli D. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104. Journal of Leukocyte Biology. 2005 Aug;78(2):359-71. |
MeSH cloud from publications including the MeSH term cancer therapy
cancer therapy
intestinal polyps
regulatory receptors
ultrasound
cytotoxic mechanisins
phosphoinositide 3-kinase
surface-molecule
activating receptors
endometrium carcinoma
natural cytotoxicity
PIN
akt
molecular-mechanisms
Onc206
Onc201
hedgehog signaling pathway
tumorigenesis
Onc212
relevance
cancer
anti-tumor immune
Atf4
antagonist
genetically-engineered mice
Genetics & Heredity
scaffold hopping
thyroid and adrenal tumors
cell death regulators
necroptosis
with the contents of this article
pkb
Parp1
mutation
in-vivo
cytotoxic lymphocytes
therapy
inflammatory pathways
Gpcr
neoplasia
Dr5
medulloblastoma
synthetic lethality
pten
immunodeficient scid mice
Smoothened
pathway
target-cells
Trail
Developmental Biology
hla-a
Chop
Ezh2
imipridone
chromatin long-range interaction
DNA damage